The flip side of patent expiration is that a rival company would need the infrastructure and capability of manufacturing the drug.
For something like Aspirin, that's not a high bar to clear, an avid experimenter could probably do that in their basement, but for gene therapy drugs I feel confident in saying that it's orders of magnitude higher.
Then again, they could kickstarter it and say that if they get X orders or raise Y money they'll do it, make and sell the 20-30k doses for everyone and then close up shop with a healthy profit.
For something like Aspirin, that's not a high bar to clear, an avid experimenter could probably do that in their basement, but for gene therapy drugs I feel confident in saying that it's orders of magnitude higher.
Then again, they could kickstarter it and say that if they get X orders or raise Y money they'll do it, make and sell the 20-30k doses for everyone and then close up shop with a healthy profit.